Effect of vitamin A supplementation on cause-specific mortality in women of reproductive age in Ghana: a secondary analysis from the ObaapaVitA trial
Lisa Hurt, Augustinus ten Asbroek, Seeba Amenga-Etego, Charles Zandoh, Samuel Danso, Karen Edmond, Chris Hurt, Charlotte Tawiah, Zelee Hill, Justin Fenty, Seth Owusu-Agyei, Oona M Campbell & Betty R Kirkwood
Volume 91, Number 1, January 2013, 19-27
Table 2. Vitamin A supplementation and mortality among women caused by specific infections or anaemia, Ghana, 2000–2008
| Cause | No. of deaths |
RR (95% CI)a | |
|---|---|---|---|
| Placebo arm | Vitamin A arm | ||
| Infection | |||
| Malaria | 21 | 24 | 1.13 (0.63–2.03) |
| Tuberculosis | 51 | 63 | 1.22 (0.84–1.78) |
| Other respiratory infection | 14 | 18 | 1.27 (0.63–2.57) |
| HIV/AIDS | 258 | 276 | 1.06 (0.88–1.26) |
| Intestinal infection | 59 | 48 | 0.80 (0.54–1.19) |
| Meningitis | 45 | 38 | 0.84 (0.54–1.29) |
| Other infectionb | 64 | 73 | 1·13 (0·81–1·58) |
| Anaemia | |||
| Haemolytic | 15 | 25 | 1.65 (0.87–3.13) |
| Other | 29 | 36 | 1.23 (0.76–1.99) |
CI, confidence interval; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; RR, rate ratio.
a Calculated, as the mortality rate in the vitamin A arm divided by that in the placebo arm, after adjusting for clustering by use of random-effects models. The data come from an intention-to-treat analysis.
b Includes hepatitis, abscess, cellulitis, rabies, tetanus, chicken pox, and septicaemia/infection of unknown etiology.